Special Notice
NAICS 325414
TECHNOLOGY LICENSING OPPORTUNITY: PlagueGuard Antibodies
Los Alamos National Laboratory scientists have developed high-affinity human antibodies that can quickly detect and potentially treat deadly, antibiotic-resistant plague infections, helping protect against both natural outbreaks and bioterror threats. The Challenge: Plague, caused by the bacterium Yersinia pestis, remains a serious threatnot just as a rare but deadly natural infection, but also as a potential bioweapon. Modern medicine relies heavily on antibiotics, but these can fail if the bacteria become resistant, which is a growing global concern. Rapid, accurate detection is also difficult, and existing diagnostic tools can produce false results or aren't practical for field use. Problems Solved: Scientists at Los Alamos National Laboratory developed high-affinity antibodies that are specifically designed to detect a key component (the F1 antigen) found in the most dangerous strains of Y. pestis. These antibodies are: Extremely sensitive and specific, detecting even tiny amounts of the plague bacterium. Designed to target two different parts of the F1 antigen, minimizing the risk of false positives. Resilient when chemically modified, allowing them to be used in both fast dia...
Notice ID: 38d0a89599544e848435aba48f15f828 ·
View on SAM.gov ↗
Explore more federal-contracting data
Browse opportunities by NAICS code · set-aside category · state & jurisdiction · buying agency
Win more federal contracts
BidChamp gives small businesses AI-powered bid writing, document analysis, and recompete forecasting - for free during your trial.
Sign up free - 14-day trial, no card required